Crinetics Pharmaceuticals Inc. is a San Diego-based clinical-stage biopharmaceutical company that develops innovative therapies for rare endocrine diseases and related tumors. The company's robust pipeline features oral and targeted drug candidates aimed at addressing significant unmet needs in the endocrine disorder market. By prioritizing research and development, Crinetics strives to establish itself as a leader in specialized endocrine treatments, ultimately enhancing patient outcomes and transforming treatment paradigms in this crucial healthcare sector. Show more

Location: 6055 LUSK BOULEVARD, SAN DIEGO, CA, UNITED STATES, 92121, San Diego, CA, 92121, USA | Website: https://www.crinetics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

5.119B

52 Wk Range

$24.10 - $57.99

Previous Close

$51.88

Open

$52.28

Volume

1,214,902

Day Range

$49.31 - $52.95

Enterprise Value

3.696B

Cash

110.9M

Avg Qtr Burn

-110.7M

Insider Ownership

1.99%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PALSONIFY™ (paltusotine) Details Acromegaly	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PALSONIFY™ (paltusotine) Details Carcinoid syndrome	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atumelnant CRN04894 (ACTH antagonist) Details Congenital adrenal hyperplasia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atumelnant CRN04894 (ACTH antagonist) Details Congenital adrenal hyperplasia	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atumelnant CRN04894 (ACTH antagonist) Details Cushing’s syndrome	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atumelnant CRN04894 (ACTH antagonist) Details Congenital adrenal hyperplasia (adult)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CRN09682 Details Metastatic/locally advanced SST2-positive neuroendocrine tumors (NETs) and other SST2-expressing solid tumors.	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CRN04777 (SST5 agonist) Details Hyperinsulinism	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.